Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
BACKGROUND
Treatment of patients with membranous glomerulonephritis (MGN) is controversial because of the lack of clear benefit of the immunosuppressive regimens on patient or renal survival. The objective of this study is to evaluate the efficacy and safety of mycophenolate mofetil (MMF) for patients with MGN.


METHODS
1-year prospective, randomized, and controlled clinical trial.


METHODS
36 patients with biopsy-proven idiopathic MGN and nephrotic syndrome.


METHODS
19 patients received MMF (2 g/d) for 12 months and 17 patients were in the control group. All patients had the same conservative treatment based on renin-angiotensin blockers, statins, low-salt and low-protein diet, and diuretics in case of edema.


METHODS
End points were the mean proteinuria over creatinuria ratio in mg/g throughout the study and numbers of complete and partial remissions at 1 year (month 12). Data were analyzed on an intention-to-treat analysis.


RESULTS
Mean proteinuria over creatinuria ratio was stable in both groups throughout the study (P = 0.1). Mean proteinuria over creatinuria ratio was 4,690 +/- 2,212 mg/g in the MMF group and 6,548 +/- 4,601 mg/g in the control group (95% confidence interval of the difference, -619 to +4,247; P = 0.1). Remission was complete in 3 patients (1 in the MMF group, 2 in the control group; P = 0.5) and partial in 11 patients (6 in the MMF group, 5 in the control group; P = 0.9). The probability of complete or partial remission did not differ between the 2 groups after 12 months (relative risk, 0.92; 95% confidence interval, 0.48 to 1.75; P = 0.7). Kidney function was stable in the 2 groups according to estimated glomerular filtration rate and serum creatinine level.


CONCLUSIONS
The small number of patients and short follow-up prevent generalizations.


CONCLUSIONS
A 12-month regimen of MMF did not decrease mean proteinuria over creatinuria ratio or increase partial and complete remissions. Serious adverse effects were observed in 4 patients (20%) receiving MMF.
Dussol
Bertrand
B
Centre de Néphrologie et de Transplantation rénale, Hôpital de la Conception et Université Aix-Marseille II, Marseille, France. bdussol@ap-hm.fr
Morange
Sophie
S
Burtey
Stéphane
S
Indreies
Monica
M
Cassuto
Elisabeth
E
Mourad
Georges
G
Villar
Emmanuel
E
Pouteil-Noble
Claire
C
Karaaslan
Huseyin
H
Sichez
Hélène
H
Lasseur
Catherine
C
Delmas
Yashou
Y
Nogier
Marie-Béatrice
MB
Fathallah
Mohamed
M
Loundou
Anderson
A
Mayor
Valérie
V
Berland
Yvon
Y
D000328:Adult; D000368:Aged; D003404:Creatinine / Q000097:blood / Q000652:urine; D004305:Dose-Response Relationship, Drug; D005260:Female; D005919:Glomerular Filtration Rate / Q000502:physiology; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D011446:Prospective Studies; D011507:Proteinuria / Q000652:urine; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D003404:Creatinine; D009173:Mycophenolic Acid